Mats Jerkeman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9340541/publications.pdf

Version: 2024-02-01

211	6,970	71102	69250
papers	citations	41 h-index	77 g-index

215	215	215	6303
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivoâ€“purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 2008, 112, 2687-2693.	1.4	571
2	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet, The, 2016, 387, 770-778.	13.7	389
3	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28, iv62-iv71.	1.2	387
4	Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood, 2014, 124, 1570-1577.	1.4	309
5	TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood, 2017, 130, 1903-1910.	1.4	296
6	Nordic <scp>MCL</scp>2 trial update: sixâ€year followâ€up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <scp>BEAM</scp> or <scp>BEAC</scp>Â+Âautologous stemâ€cell support: still very long survival but late relapses do occur. British Journal of Haematology, 2012, 158, 355-362.	2.5	241
7	Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Modern Pathology, 2005, 18, 1113-1120.	5.5	185
8	Nuclear expression of the nonâ€“B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood, 2008, 111, 800-805.	1.4	185
9	15â€year followâ€up of the Second Nordic Mantle Cell Lymphoma trial (<scp>MCL</scp>2): prolonged remissions without survival plateau. British Journal of Haematology, 2016, 175, 410-418.	2.5	170
10	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood, 2010, 115, 1530-1533.	1.4	167
11	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2021, 32, 298-308.	1.2	127
12	Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma. Journal of Clinical Oncology, 2009, 27, 4365-4370.	1.6	123
13	Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematology,the, 2018, 5, e109-e116.	4.6	117
14	Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood, 2014, 124, 1288-1295.	1.4	113
15	SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma â€“ a Nordic Lymphoma Group study. British Journal of Haematology, 2014, 166, 98-108.	2.5	110
16	Antagonistic Human FcÎ³RIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy InÂVivo. Cancer Cell, 2015, 27, 473-488.	16.8	108
17	Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood, 2003, 101, 4047-4054.	1.4	99
18	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Annals of Oncology, 2013, 24, 1385-1392.	1.2	99

#	Article	IF	Citations
19	Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Modern Pathology, 2009, 22, 1094-1101.	5.5	97
20	KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica, 2020, 105, 1604-1612.	3.5	96
21	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood, 2014, 123, 2953-2959.	1.4	90
22	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. New England Journal of Medicine, 2022, 386, 2482-2494.	27.0	83
23	Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*. European Journal of Haematology, 2011, 86, 124-128.	2.2	80
24	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood, 2016, 128, 1814-1820.	1.4	75
25	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danishâ€“Swedish Population-Based Study. Journal of Clinical Oncology, 2015, 33, 3993-3998.	1.6	74
26	Phase II trial of zanolimumab (HuMaxâ€CD4) in relapsed or refractory nonâ€cutaneous peripheral T cell lymphoma. British Journal of Haematology, 2010, 150, 565-573.	2.5	73
27	Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia, 2018, 32, 1799-1803.	7.2	67
28	Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Annals of Oncology, 2013, 24, 1879-1886.	1.2	65
29	Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma?a Nordic Lymphoma Group study. Annals of Hematology, 2004, 83, 414-419.	1.8	61
30	Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clinical Cancer Research, 2003, 9, 722-8.	7.0	60
31	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and) Tj ETQq1 1 0.784314 rgBT /Over 428-435.	2.0	56
32	High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood, 2005, 105, 2908-2915.	1.4	54
33	Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-Î² II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leukemia and Lymphoma, 2007, 48, 2221-2232.	1.3	52
34	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. Journal of Clinical Oncology, 2017, 35, 4019-4026.	1.6	50
35	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive Bâ€cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2018, 182, 583-586.	2.5	49
36	CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial. Annals of Oncology, 1999, 10, 1079-1086.	1.2	48

#	Article	IF	Citations
37	Bacteremic and non-bacteremic febrile urinary tract infection â€" a review of 168 hospital-treated patients. Infection, 1992, 20, 143-145.	4.7	45
38	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. Blood, 2015, 125, 2669-2677.	1.4	44
39	Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. Blood, 2015, 126, 36-41.	1.4	44
40	Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressiveÂB-cell lymphoma. Blood, 2022, 139, 1863-1877.	1.4	43
41	Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Leukemia and Lymphoma, 2011, 52, 1929-1935.	1.3	42
42	Health-Related Quality of Life and Its Potential Prognostic Implications in Patients with Aggressive Lymphoma. Medical Oncology, 2001, 18, 85-94.	2.5	41
43	Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. American Journal of Hematology, 2009, 84, 803-808.	4.1	41
44	Survival in patients with intermediate or high grade non-Hodgkinâ€™s lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. British Journal of Cancer, 2001, 84, 303-307.	6.4	40
45	Targeting of Bâ€cell receptor signalling in Bâ€cell malignancies. Journal of Internal Medicine, 2017, 282, 415-428.	6.0	37
46	Longâ€term survival in young and middleâ€aged <scp>H</scp>odgkin lymphoma patients in <scp>S</scp>weden 1992â€"2009â€"trends in cure proportions by clinical characteristics. American Journal of Hematology, 2015, 90, 1128-1134.	4.1	36
47	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. Oncologist, 2019, 24, e1236-e1250.	3.7	36
48	Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. British Journal of Haematology, 2008, 141, 423-432.	2.5	35
49	Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up timeâ€"a population-based comparative study. Journal of Cancer Survivorship, 2015, 9, 599-609.	2.9	35
50	Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. Blood Advances, 2020, 4, 1906-1915.	5.2	35
51	ICE (ifosfamide, carboplatin, etoposide) as secondâ€line chemotherapy in relapsed or primary progressive aggressive lymphoma â€" the Nordic Lymphoma Group experience. European Journal of Haematology, 2004, 73, 179-182.	2.2	33
52	Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. Blood Cancer Journal, 2021, 11, 9.	6.2	32
53	Bclâ€2 but not FOXP1, is an adverse risk factor in immunochemotherapyâ€treated nonâ€germinal center diffuse large Bâ€cell lymphomas. European Journal of Haematology, 2009, 82, 364-372.	2.2	31
54	p53 is associated with highâ€risk and pinpointsTP53missense mutations in mantle cell lymphoma. British Journal of Haematology, 2020, 191, 796-805.	2.5	31

#	Article	IF	Citations
55	Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. European Journal of Haematology, 2007, 79, 146-149.	2.2	29
56	Treatment outcome in T-cell lymphoblastic lymphoma in adults â€“ a population-based study from the Swedish Lymphoma Registry. Acta OncolÃ³gica, 2014, 53, 927-934.	1.8	28
57	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danishâ€Swedish populationâ€based observational study. British Journal of Haematology, 2016, 173, 236-244.	2.5	28
58	The addition of etoposide to <scp>CHOP</scp> is associated with improved outcome in <scp>ALK</scp>+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. British Journal of Haematology, 2017, 178, 739-746.	2.5	28
59	Simplicity at the cost of predictive accuracy in diffuse large Bâ€cell lymphoma: a critical assessment of the Râ€<scp>IPI</scp>,<scp> IPI</scp>, and <scp>NCCN</scp>â€<scp>IPI</scp>. Cancer Medicine, 2018, 7, 114-122.	2.8	28
60	Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study. JCO Clinical Cancer Informatics, 2018, 2, 1-13.	2.1	27
61	Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large Bâ€cell lymphoma: a Swedish lymphoma register study. Journal of Internal Medicine, 2019, 285, 455-468.	6.0	27
62	Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL. Blood, 2020, 135, 2000-2004.	1.4	26
63	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Advances, 2017, 1, 2257-2268.	5.2	25
64	Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leukemia and Lymphoma, 2011, 52, 2090-2096.	1.3	24
65	Trends in the prevalence, incidence and survival of nonâ€Hodgkin lymphoma subtypes during the 21st century â€“ a Swedish lymphoma register study. British Journal of Haematology, 2020, 189, 1083-1092.	2.5	24
66	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leukemia and Lymphoma, 2018, 59, 1814-1828.	1.3	23
67	Longâ€term survival and loss in expectancy of life in a populationâ€based cohort of 7114 patients with diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2018, 93, 1020-1028.	4.1	23
68	B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Letters, 2008, 259, 138-145.	7.2	22
69	Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID). Blood Advances, 2018, 2, 1386-1392.	5.2	22
70	CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2007, 48, 1774-1779.	1.3	21
71	Prognostic implications of cytogenetic aberrations in diffuse large Bâ€cell lymphomas. European Journal of Haematology, 1999, 62, 184-190.	2.2	21
72	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplantation, 2021, 56, 2911-2921.	2.4	21

#	Article	IF	Citations
73	Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer. PLoS ONE, 2015, 10, e0121300.	2.5	21
74	Prognostic impact of protein kinase C Î² II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. Modern Pathology, 2010, 23, 686-693.	5.5	20
75	The impact of age on survival of diffuse large B-cell lymphoma â€“ a population-based study. Acta OncolÃ³gica, 2015, 54, 916-923.	1.8	20
76	High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis. Blood, 2022, 139, 1557-1563.	1.4	20
77	Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma. PLoS ONE, 2014, 9, e91031.	2.5	19
78	Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma â€“ a Swedish population-based study. Acta OncolÃ³gica, 2015, 54, 924-932.	1.8	19
79	Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. Leukemia, 2016, 30, 1428-1430.	7.2	19
80	Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. Leukemia and Lymphoma, 2017, 58, 2815-2823.	1.3	19
81	Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. Haematologica, 2018, 103, e541-e543.	3.5	19
82	High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial. Leukemia and Lymphoma, 2014, 55, 1206-1208.	1.3	18
83	Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo. Experimental Hematology and Oncology, 2015, 4, 4.	5.0	18
84	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. HemaSphere, 2021, 5, e510.	2.7	18
85	Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment. Acta OncolÃ³gica, 2015, 54, 1770-1780.	1.8	17
86	An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. Cancer Medicine, 2020, 9, 663-670.	2.8	17
87	Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study. Leukemia and Lymphoma, 2014, 55, 1838-1843.	1.3	16
88	Outcomes of relapsed/refractory diffuse large Bâ€cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second lineâ€”A populationâ€based study of 736 patients. British Journal of Haematology, 2022, 198, 267-277.	2.5	16
89	Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines. Experimental Cell Research, 2011, 317, 1179-1191.	2.6	15
90	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. American Journal of Hematology, 2016, 91, 894-899.	4.1	15

#	Article	IF	Citations
91	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. Leukemia and Lymphoma, 2017, 58, 2824-2832.	1.3	15
92	Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays. Leukemia Research, 2014, 38, 682-690.	0.8	14
93	Chemotherapeutic intensity and survival differences in young patients with diffuse large Bâ€cell lymphoma: a Swedish Lymphoma Registry study. British Journal of Haematology, 2016, 175, 614-622.	2.5	14
94	A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia. Npj Precision Oncology, 2018, 2, 18.	5.4	14
95	Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial. Blood, 2019, 134, 2816-2816.	1.4	14
96	Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. Experimental Hematology and Oncology, 2019, 8, 16.	5.0	13
97	Comorbidities and sex differences in causes of death among mantle cell lymphoma patients â€“ A nationwide populationâ€based cohort study. British Journal of Haematology, 2020, 189, 106-116.	2.5	13
98	Zanolimumab (HuMax-CD4â„¢), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma.. Blood, 2007, 110, 3409-3409.	1.4	13
99	Residual Mass in Aggressive Lymphoma - Does Size, Measured by Computed Tomography, Influence Clinical Outcome?. Acta OncolÃ³gica, 2000, 39, 485-489.	1.8	12
100	Impact on survival of addition of etoposide to primary chemotherapy in diffuse large Bâ€cell lymphoma: a Swedish Lymphoma Registry study. Hematological Oncology, 2017, 35, 151-157.	1.7	12
101	Infiltration of CD163â€, PDâ€L1â€and FoxP3â€positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. British Journal of Haematology, 2021, 193, 520-531.	2.5	12
102	Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients > 65 Years with Mantle Cell Lymphoma: Results From the Phase I Portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Trial. Blood, 2011, 118, 2700-2700.	1.4	12
103	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. Blood, 2016, 128, 148-148.	1.4	12
104	High serum vascular endothelial growth factor level is an adverse prognostic factor for highâ€risk diffuse large <scp>B</scp>â€cell lymphoma patients treated with doseâ€dense chemoimmunotherapy. European Journal of Haematology, 2012, 89, 395-402.	2.2	11
105	Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up. PLoS ONE, 2018, 13, e0202651.	2.5	11
106	EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic. HemaSphere, 2021, 5, e529.	2.7	11
107	Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. Leukemia, 2022, 36, 177-188.	7.2	11
108	Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy For Patients >65 Years With Mantle Cell Lymphoma: Preliminary Results From The Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I-II Trial. Blood, 2013, 122, 4377-4377.	1.4	11

#	Article	IF	Citations
109	Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. International Journal of Oncology, 2002, 20, 161-5.	3.3	10
110	Impact of comorbidity on survival in peripheral Tâ€cell lymphomas: A Swedish Lymphoma Registry study. Hematological Oncology, 2018, 36, 159-165.	1.7	10
111	Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study. Annals of Oncology, 2018, 29, 1882-1883.	1.2	10
112	Outcome and determinants of failure to complete primary <scp>Râ€CHOP</scp> treatment for reasons other than nonâ€response among patients with diffuse large Bâ€cell lymphoma. American Journal of Hematology, 2020, 95, 740-748.	4.1	10
113	Mantle Cell Lymphoma of Mucosaâ€Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. HemaSphere, 2020, 4, e302.	2.7	10
114	Myocardial infarction in diffuse large Bâ€cell lymphoma patients â€“ a populationâ€based matched cohort study. Journal of Internal Medicine, 2021, 290, 1048-1060.	6.0	10
115	Association between anthropometry and lifestyle factors and risk of Bâ€cell lymphoma: An exposomeâ€wide analysis. International Journal of Cancer, 2021, 148, 2115-2128.	5.1	9
116	Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen â€“ a real world study on patients diagnosed in Sweden 2007-2017. Haematologica, 2022, 107, 740-743.	3.5	9
117	Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. European Journal of Nutrition, 2020, 59, 813-823.	3.9	8
118	Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival. Blood Advances, 2021, 5, 1638-1647.	5.2	8
119	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 720-728.	1.2	7
120	Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible. Blood, 2020, 136, 15-15.	1.4	7
121	Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition. American Journal of Epidemiology, 2019, 188, 274-281.	3.4	6
122	Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials. Blood, 2013, 122, 3367-3367.	1.4	6
123	Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).. Journal of Clinical Oncology, 2022, 40, LBA7502-LBA7502.	1.6	6
124	Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study. Blood Cancer Journal, 2016, 6, e501-e501.	6.2	5
125	Longâ€term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with highâ€dose melphalanâ€”two case studies. European Journal of Haematology, 2016, 96, 541-543.	2.2	5
126	Clinical Characteristics and Histopathological Patterns of Hodgkin Lymphoma and Treatment Outcomes at a Tertiary Cancer Center in Ethiopia. JCO Global Oncology, 2021, 7, 277-288.	1.8	5

#	Article	IF	Citations
127	Idelalisib in relapsed/refractory diffuse large Bâ€cell lymphoma: results from a Nordic Lymphoma Group phase II trial. British Journal of Haematology, 2022, 196, 437-440.	2.5	5
128	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. Blood, 2020, 136, 36-36.	1.4	5
129	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).. Journal of Clinical Oncology, 2014, 32, 8529-8529.	1.6	5
130	Advances in immune therapies in hematological malignancies. Journal of Internal Medicine, 2022, 292, 205-220.	6.0	5
131	Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.. Blood, 2007, 110, LB1-LB1.	1.4	5
132	IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY. Hematological Oncology, 2017, 35, 143-144.	1.7	4
133	Frequency and clinical implications of SOX11 expression in Burkitt lymphoma. Leukemia and Lymphoma, 2017, 58, 1760-1763.	1.3	4
134	Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-ÎºB activity. BMC Cancer, 2018, 18, 466.	2.6	4
135	Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study. International Journal of Cancer, 2020, 147, 1649-1656.	5.1	4
136	Nordic Mantle Cell Lymphoma (MCL) Project: Prolonged Follow-Up of 86 Patients Treated with BEAM/BEAC + PBSCT Confirms That Addition of High-Dose Ara-C and Rituximab to CHOP Induction + In-Vivo Purging with Rituximab Increases Clinical and Molecular Response Rates, PCR-Neg. Grafts, Failure-Free, Relapse-Free and Overall Survival.. Blood, 2004, 104, 8-8.	1.4	4
137	90y-Ibritumumab Tiuxetan (Zevalin Â®)-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. â€“ Preliminary Results From the Third Nordic MCL Phase II Study (MCL3).. Blood, 2009, 114, 932-932.	1.4	4
138	Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up. Blood, 2016, 128, 1095-1095.	1.4	4
139	Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years. Blood, 2016, 128, 146-146.	1.4	4
140	National e-library for standardized chemotherapy regimens. Acta OncolÃ³gica, 2020, 59, 1079-1083.	1.8	3
141	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. BMC Cancer, 2020, 20, 1202.	2.6	3
142	Detecting deviations from the efficacy and safety results of singleâ€arm trials using realâ€world data: The case of a CARâ€T cell therapy in Bâ€cell lymphoma. Pharmacoepidemiology and Drug Safety, 2021, 30, 514-519.	1.9	3
143	Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden. Blood, 2019, 134, 4111-4111.	1.4	3
144	Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL). Blood, 2015, 126, 469-469.	1.4	3

#	Article	IF	Citations
145	Season of diagnosis is associated with overall survival in patients with diffuse large Bâ€cell lymphoma but not with Hodgkin's lymphoma â€“ A populationâ€based Swedish Lymphoma Register study. European Journal of Haematology, 2016, 97, 393-398.	2.2	2
146	Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases. Pharmaceutical Medicine, 2019, 33, 83-88.	1.9	2
147	Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets. Leukemia and Lymphoma, 2021, 62, 2637-2647.	1.3	2
148	Impact of comorbidity in elderly patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients. Blood Advances, 2021, , .	5.2	2
149	R-CHOEP-14 Ã— 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2â€“3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18â€“65 Years.. Blood, 2010, 116, 2805-2805.	1.4	2
150	Dose-Dense Chemoimmunotherapy and Early Central Nervous System Prophylaxis For High-Risk Diffuse Large B-Cell Lymphoma. â€“Preliminary Results From a Nordic Phase II Study. Blood, 2013, 122, 849-849.	1.4	2
151	Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial). Blood, 2016, 128, 1854-1854.	1.4	2
152	Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEACÂ+Âautologous stem-cell support: still very long survival but. British Journal of Haematology, 2012, 158, 815-816.	2.5	1
153	Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?. Annals of Lymphoma, 2019, 3, 2-2.	4.5	1
154	Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women. Anticancer Research, 2020, 40, 1513-1517.	1.1	1
155	The DLBCL90 geneâ€expression assay identifies doubleâ€hit lymphomas with high sensitivity in patients from two phase II clinical trials with highâ€risk diffuse large Bâ€cell lymphoma. EJHaem, 2021, 2, 107-111.	1.0	1
156	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. Cancer Reports, 2021, , e1524.	1.4	1
157	Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden. Blood, 2018, 132, 2975-2975.	1.4	1
158	Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients. Blood, 2018, 132, 930-930.	1.4	1
159	A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies. Blood, 2019, 134, 1495-1495.	1.4	1
160	Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial. Blood, 2020, 136, 33-33.	1.4	1
161	Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden. Blood, 2020, 136, 38-39.	1.4	1
162	Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL).. Blood, 2006, 108, 2723-2723.	1.4	1

#	Article	IF	Citations
163	Addition of Etoposide to CHOP Is Associated with Improved Outcome in Adult Anaplastic Large Cell Lymphoma Patients: A Nordic Lymphoma Group Study. Blood, 2015, 126, 340-340.	1.4	1
164	Resistance to Cytarabine in Mantle Cell Lymphoma Is Mediated By Down-Regulation of Deoxycytidine Kinase at the Protein Level. Blood, 2016, 128, 1769-1769.	1.4	1
165	SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).. Blood, 2005, 106, 3356-3356.	1.4	1
166	Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.. Blood, 2005, 106, 2429-2429.	1.4	1
167	Patterns of Central Nervous System Relapse in Peripheral T-Cell Lymphomas â€“ Population-Based Data from the Swedish Lymphoma Registry. Blood, 2014, 124, 1632-1632.	1.4	1
168	Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study. Blood, 2019, 134, 1481-1481.	1.4	1
169	Preâ€treatment healthâ€related quality of life parameters have prognostic impact in patients >65Âyears with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENAâ€BERIT) experience. Hematological Oncology, 2022, 40, 23-31.	1.7	1
170	Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 655-666.	2.8	1
171	17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgriib, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab. Blood, 2020, 136, 36-37.	1.4	1
172	The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726.	2.7	1
173	DOSE-DENSE CHEMOIMMUNOTHERAPY AND CNS PROPHYLAXIS IN PATIENTS WITH HIGH-RISK DLBCL: A COMPARISON OF NORDIC CRY-04 AND CHIC STUDIES. Hematological Oncology, 2017, 35, 199-200.	1.7	0
174	MANTLE CELL LYMPHOMA OF MUCOSAâ€ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK. Hematological Oncology, 2017, 35, 202-203.	1.7	0
175	BORTEZOMIB PREVENTS DEVELOPMENT OF CYTARABINE RESISTANCE IN A MANTLE CELL LYMPHOMA IN VITRO MODEL. Hematological Oncology, 2017, 35, 400-401.	1.7	0
176	THE IMMUNE MICROENVIRONMENT AS A PROGNOSTIC TOOL FOR MCL PATIENTS. Hematological Oncology, 2019, 37, 344-345.	1.7	0
177	PHASE 1/2A CLINICAL TRIALS OF BI-1206, A MONOCLONAL ANTIBODY TO FCÎ“RIIB, ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH B-CELL MALIGNANCIES. Hematological Oncology, 2019, 37, 520-521.	1.7	0
178	EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH-RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME. Hematological Oncology, 2019, 37, 242-242.	1.7	0
179	SERUM BIOMARKERS ARE ASSOCIATED WITH TREATMENT RESPONSE IN RELAPSED MANTLE CELL LYMPHOMA. Hematological Oncology, 2019, 37, 403-403.	1.7	0
180	EVOLUTION OF CLONAL HEMATOPOIESIS IN MANTLE CELL LYMPHOMA PATIENTS BEFORE, DURING, AND AFTER INDUCTION CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION. Hematological Oncology, 2019, 37, 239-240.	1.7	0

#	Article	IF	Citations
181	YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS. Hematological Oncology, 2019, 37, 132-132.	1.7	0
182	How should we use ibrutinib in patients with mantle cell lymphoma?. British Journal of Haematology, 2021, 193, 445-446.	2.5	0
183	Genes and Proteins Associated with the Tumor Microenvironment Are Differentially Expressed in Cured Versus Primary Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma.. Blood, 2007, 110, 3171-3171.	1.4	0
184	Epidemiology and 15-Year Follow up after Cladribine Treatment of Patients with Hairy Cell Leukemia (HCL): Population-Based Swedish Data and Long-Term Follow-up of Scandinavian Study Patients Identify Older Patients with Poorer Outcome. Blood, 2008, 112, 4166-4166.	1.4	0
185	Simvastatin Sensitizes Bcl-2-Negative DLBCL Cell Lines to CHOP: A Finding with Possible Clinical Implications for Treatment of Bcl-2-Negative DLBCL?. Blood, 2008, 112, 5044-5044.	1.4	0
186	R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2â€“3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years. Blood, 2008, 112, 3604-3604.	1.4	0
187	Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2012, 30, 8074-8074.	1.6	0
188	Real World Data On Primary Treatment For Mantle Cell Lymphoma 2000-2011 â€“ a Nordic Lymphoma Group Observational Study. Blood, 2013, 122, 4358-4358.	1.4	0
189	Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort. Blood, 2013, 122, 4272-4272.	1.4	0
190	Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials. Blood, 2014, 124, 2994-2994.	1.4	0
191	Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study. Blood, 2014, 124, 1618-1618.	1.4	0
192	The Prognostic Impact of Comorbidity in Peripheral T-Cell Lymphomas: a Swedish Lymphoma Registry Study. Blood, 2014, 124, 1635-1635.	1.4	0
193	R-CHOEP-14 Is Associated with Superior Overall Survival Compared to R-CHOP-21 and R-CHOP-14 in Patients with DLBCL â‰¥70 Years â€“ a Swedish Lymphoma Registry Population Based Study. Blood, 2014, 124, 4427-4427.	1.4	0
194	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. Blood, 2015, 126, 3865-3865.	1.4	0
195	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. Blood, 2015, 126, 1501-1501.	1.4	0
196	Frequency and Clinical Implication of SOX11 Expression in Burkitt Lymphoma. Blood, 2015, 126, 5039-5039.	1.4	0
197	Valproate in Combination with Rituximab and CHOP As First Line Therapy in Diffuse Large B-Cell Lymphoma (VALFRID): Preliminary Results from a Phase I Trial with a Dose Expansion Cohort. Blood, 2015, 126, 3939-3939.	1.4	0
198	Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus. Blood, 2015, 126, 1542-1542.	1.4	0

#	Article	IF	Citations
199	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. Blood, 2016, 128, 920-920.	1.4	0
200	Prognostic Implications of Specific Comorbidities in Mantle Cell Lymphoma Patients, a Swedish Lymphoma Registry Study. Blood, 2018, 132, 2891-2891.	1.4	0
201	SAMHD1 Is Variably Expressed in Mantle Cell Lymphoma and Correlated to SOX11 but Not to Survival. Blood, 2018, 132, 4136-4136.	1.4	0
202	Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2018, 132, 4200-4200.	1.4	0
203	Clinical Characteristics and Outcomes Among Very Elderly Patients with Major Lymphoma Subtypes: A Nordic Lymphoma Group Study. Blood, 2018, 132, 571-571.	1.4	0
204	Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden. Blood, 2019, 134, 399-399.	1.4	0
205	Autologous Stem Cell Transplantation in Mantle Cell Lymphoma - Selection Mechanisms and Survival By Age Group. Blood, 2019, 134, 4572-4572.	1.4	0
206	The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy. Blood, 2019, 134, 1485-1485.	1.4	0
207	Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience. Blood, 2020, 136, 8-9.	1.4	0
208	Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgriib Antibody Administration. Blood, 2020, 136, 4-5.	1.4	0
209	Unraveling Actionable Target Mutations in Formalin Fixed Tissue in Mantle Cell Lymphoma. Blood, 2020, 136, 25-26.	1.4	0
210	Impact of Comorbidities on Outcomes of Peripheral T Cell Lymphoma in Elderly Patients: An International Retrospective Study. Blood, 2020, 136, 27-28.	1.4	0
211	Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL Complete Project. Blood, 2020, 136, 3-4.	1.4	0